Fox™-Based HRPF Applications in
Biopharmaceutical Discovery & Development

The Fox Protein Footprinting System provides actionable results throughout the drug discovery and development pipeline. Using the Fox approach, you can realize massive savings in time and money, experience robust and reproducible data generation and analysis, and enjoy a much simplified and faster workflow.
The application of Fox technology in biopharmaceutical discovery and development is continuously expanding, and our customers have generated valuable results from drug-binding, mAb therapeutics, conformational analysis, biosimilar assessment, expression/harvest optimization, aggregation, thermal stability, and formulation studies.

Discovery Applications

Rx Binding Validation
•  Orthosteric
•  Allosteric
•  Conformational Change
•  GPCR cascade

mAb Therapeutics
•  Epitope Mapping
•  Paratope Mapping
•  Affinity Determination

Conformational Analysis
•  Confomer Detection
•  Discrete Functional Analysis

Biosimilar Assessment
•  Candidate validation via HOS

Development Applications

Expression/Harvest Optimization
•  HOS Integrity at Peptide/Residue Levels
•  Differential Process Analysis

Therapeutic Aggregation
•  Interactive Domains/Residues
•  Excipient/Amino Acid Effects

Thermal Stability
•  Thermal-Induced Changes in Conformation

Therapeutic Formulation
•  Concentration
•  Excipients
•  Conformational Change
•  Delivery System

Spotlight on Protein Aggregation

Understanding protein-protein interactions so researchers can develop high concentration biotherapeutics

Facing the Noncompliance Challenge

Therapeutics which require protracted and often painful intravenous administration can result in medication noncompliance by patients. When the drug delivery experience is unpleasant, avoidance is common, especially among patients with chronic disease.

In response to this challenge, biopharmaceutical companies strive to develop antibodies and other protein formulations containing high concentrations of therapeutics so that a single, small intramuscular or subcutaneous injection is efficacious.

However, high antibody concentration pushes the molecules closer together causing molecular crowding. In turn, crowding increases the propensity for protein-protein interactions that can disrupt the hydrogen bonding matrix, induce protein misfolding, and can eventually manifest as antibody aggregation.

When developing high concentrations of antibodies, it is essential to pinpoint the interfacial domains of protein interaction by conducting protein aggregation studies. By understanding antibody Higher Order Structure (HOS), the antibody formulation can be optimized to limit aggregation.

Identifying Interfacial Domains of mAb Aggregation Using Fox™-Based HRPF

The Flash Oxidation (Fox™) Protein Footprinting System is gaining momentum in protein interaction studies because of its robust, yet relatively simple workflow that produces actionable results such as identifying excipients that can stabilize high concentrations of antibodies by limiting protein intermolecular interactions.

A differential Fox-based HRPF experiment compared the change in oxidation between an aggregated antibody formulation and a non-aggregated formulation that contained an amino acid excipient. The results showed that peptides involved in the intermolecular interactions for the aggregated samples were protected from •OH modification, whereas with the addition of the amino acid, many of those same peptides were exposed to •OH attack.

Employing a volcano plot, the peptides with significant change in oxidation were easily identified. Several peptides significantly increased in oxidation following amino acid addition. The figure shown highlights the substantial intermolecular interactions that predominated and were ultimately disrupted by the addition of the amino acid. Armed with this powerful data, drug researchers can make further improvements to antibody design and formulation.

Volcano plot comparing the change in oxidation before and after the addition of an amino acid.

Peptides with a p-value of ≤0.05 are plotted above the dotted line. Peptides highlighted in blue have a fold change of less than two and peptides highlighted in green have a fold change equal to or greater than two. Peptides with a positive fold change increased in oxidation following the amino acid addition while a negative fold change indicates a decrease in oxidation.

Download WHite Paper

Presented by
Emily Chea, PhD

FASEB’s Protein Aggregation Conference:
Function, Dysfunction, and Disease

Spend less than 10-minutes with Dr. Chea as she reviews how the Flash Oxidation (Fox™) Protein Footprinting System characterizes monoclonal antibody (mAb) aggregation and determines how excipients help stabilize the protein.


Request a custom HRPF webinar for your lab.

Request Webinar